Gilman Law LLP, a leading national securities fraud law firm, is investigating claims on behalf of investors of Medtox Scientific, Inc. (“Medtox” or the “Company”) (MTOX) concerning the proposed acquisition of Medtox by Laboratory Corporation of America Holdings in a cash transaction valued at approximately $241 million.
Medtox Lawsuit Investigation
The Medtox Lawsuit Investigation concerns whether the Medtox directors breached their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the Medtox acquisition agreement, Medtox shareholders would receive $27.00 in cash per share of Medtox common stock. However, a number of factors, including price to Revenues, Cash Flow, and EBITDA, are below that of comparable transactions.
Legal Help for Medtox (MTOX) Investors and Current MTOX Shareholders
Investment Losses Law Firm Gilman Law LLP
The investment losses and securities fraud lawyers of Gilman Law LLP have over 33 years of experience in securities class action lawsuits and have been involved in all major aspects of securities litigation. Our shareholder rights attorneys focuses on cases involving stock manipulation, securities fraud, investments fraud, shareholder rights violations, and securities arbitration.